What's in Haffkine Bio-Pharmaceutical Corporation Ltd.'s pipeline?

Haffkine Bio-Pharmaceutical Corporation Ltd. has 2 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Haffkine Bio-Pharmaceutical Corporation Ltd.'s portfolio?

Top competitors by shared drug class: Brian J Lipworth, CEL-SCI Corporation, CHU de Quebec-Universite Laval, Eli Lilly and Company, Hospital Authority, Hong Kong.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/haffkine-bio-pharmaceutical-corporation-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Haffkine Bio-Pharmaceutical Corporation Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Haffkine Bio-Pharmaceutical Corporation Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
AScVS + Prazosin	AScVS + Prazosin	phase 3	Cancer immunotherapy vaccine		Oncology
T.Prazosin	T.Prazosin	phase 3	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor	Cardiovascular

Therapeutic area mix

Cardiovascular · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Brian J Lipworth · 1 shared drug class
CEL-SCI Corporation · 1 shared drug class
CHU de Quebec-Universite Laval · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
Hospital Authority, Hong Kong · 1 shared drug class
Immodulon Therapeutics Ltd · 1 shared drug class
Japan Heart Foundation · 1 shared drug class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Haffkine Bio-Pharmaceutical Corporation Ltd.:

Cite this brief

Drug Landscape (2026). Haffkine Bio-Pharmaceutical Corporation Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/haffkine-bio-pharmaceutical-corporation-ltd. Accessed 2026-05-17.